Novel anti-somatostatin receptor 2 antibody-drug conjugate for neuroendocrine cancer therapy
Si, Y.; Guenter, R.; Ou, J.; Kim, S.; Ernst, P.; Carter, A. M.; Bibb, J. A.; Markert, J. M.; Jaskula-Sztul, R.; Zhou, L.; Chen, H.; Liu, X.
Show abstract
Neuroendocrine (NE) cancers include a diverse spectrum of hormone-secreting neoplasms that arise from the endocrine and nervous systems. Current chemo- and radio- therapies have marginal curative benefits. This study aimed to develop an innovative antibody-drug conjugate (ADC) to effectively treat NE tumors (NETs). We first confirmed that somatostatin receptor 2 (SSTR2) is an ideal surface target by analyzing 38 patient-derived NET tissues, 33 normal organs, and 3 NET cell lines. We then developed a new monoclonal antibody (mAb, IgG1 and kappa) to target two extracellular domains of SSTR2, which showed strong and specific surface binding to NETs. The ADC was constructed by conjugating the anti-SSTR2 mAb and antimitotic monomethyl auristatin E. In vitro evaluations indicated that the ADC can effectively bind, internalize, release payload, and kill NET cells effectively. Finally, the ADC was evaluated in vivo using a NET xenografted mouse model to determine cancer targeting, maximal tolerated dosage, pharmacokinetics, and anti-cancer efficacy. The anti-SSTR2 ADC was able to exclusively target and kill NETs with minimal toxicity and high stability in vivo. This study demonstrates that the anti-SSTR2 mAb-based ADC has high therapeutic values for NET therapy.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease 92%
- Combinatorial Intracellular Delivery Screening (CIDS) of Anticancer Drugs 91%
- Investigating the in vivo biodistribution of extracellular vesicles isolated from various human cell sources using positron emission tomography 90%
Similar papers in this journal
Similar papers in this journal
- TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy 94%
- Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer 93%
- Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX 93%
Similar papers in this journal
- Statin-dye conjugates for selective targeting of KRAS mutant cancer cells 94%
- Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides 92%
- A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment. 92%
Similar papers in this journal
- Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in GBM 92%
- A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas 92%
- Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.